Booster Innovation Fund adds Orbis Diagnostics to its investment portfolio.
Booster is pleased to announce the addition of Orbis Diagnostics to the Booster Innovation Fund (BIF) portfolio, Orbis Diagnostics (formed in 2016) operates in the life sciences and medical technologies sector. It specialises in the development of point of care diagnostics. It’s ‘lab in a box’ testing platform uses its microfluidic disk to miniaturise and automate accurate lab testing for use at points of need. The company is classified as early expansion stage.
BIF will make a cash investment of $250,000. Following this transaction (and issue of additional units to fund the purchase), Orbis Diagnostics will represent 3% of BIF’s investment portfolio of 21 companies, and with a net asset value of over $8.1m.
Investors can continue to purchase units in BIF on the NZX or can subscribe for units in the fund as part of the process described in the fund’s Product Disclosure Statement (PDS) that is available at www.booster.co.nz